244 related articles for article (PubMed ID: 12072044)
1. Testicular dose and fertility in men following I(131) therapy for thyroid cancer.
Hyer S; Vini L; O'Connell M; Pratt B; Harmer C
Clin Endocrinol (Oxf); 2002 Jun; 56(6):755-8. PubMed ID: 12072044
[TBL] [Abstract][Full Text] [Related]
2. Prognosis for fertility and ovarian function after treatment with radioiodine for thyroid cancer.
Vini L; Hyer S; Al-Saadi A; Pratt B; Harmer C
Postgrad Med J; 2002 Feb; 78(916):92-3. PubMed ID: 11807191
[TBL] [Abstract][Full Text] [Related]
3. Testicular function after radioiodine therapy for thyroid carcinoma.
Wichers M; Benz E; Palmedo H; Biersack HJ; Grünwald F; Klingmüller D
Eur J Nucl Med; 2000 May; 27(5):503-7. PubMed ID: 10853804
[TBL] [Abstract][Full Text] [Related]
4. Radiation dose to the testes after 131I therapy for ablation of postsurgical thyroid remnants in patients with differentiated thyroid cancer.
Ceccarelli C; Battisti P; Gasperi M; Fantuzzi E; Pacini F; Gualdrini G; Pierantoni MC; Luciani A; Djokich D; Pinchera A
J Nucl Med; 1999 Oct; 40(10):1716-21. PubMed ID: 10520714
[TBL] [Abstract][Full Text] [Related]
5. Gonadal effect of radiation from 131I in male patients with thyroid carcinoma.
Krassas GE; Pontikides N
Arch Androl; 2005; 51(3):171-5. PubMed ID: 16025855
[TBL] [Abstract][Full Text] [Related]
6. Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine.
Pacini F; Gasperi M; Fugazzola L; Ceccarelli C; Lippi F; Centoni R; Martino E; Pinchera A
J Nucl Med; 1994 Sep; 35(9):1418-22. PubMed ID: 8071685
[TBL] [Abstract][Full Text] [Related]
7. High-dose radioiodine treatment for differentiated thyroid carcinoma is not associated with change in female fertility or any genetic risk to the offspring.
Bal C; Kumar A; Tripathi M; Chandrashekar N; Phom H; Murali NR; Chandra P; Pant GS
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):449-55. PubMed ID: 16095849
[TBL] [Abstract][Full Text] [Related]
8. Impact on testicular function of a single ablative activity of 3.7 GBq radioactive iodine for differentiated thyroid carcinoma.
Bourcigaux N; Rubino C; Berthaud I; Toubert ME; Donadille B; Leenhardt L; Petrot-Keller I; Brailly-Tabard S; Fromigué J; de Vathaire F; Simon T; Siffroi JP; Schlumberger M; Bouchard P; Christin-Maitre S
Hum Reprod; 2018 Aug; 33(8):1408-1416. PubMed ID: 29912343
[TBL] [Abstract][Full Text] [Related]
9. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma.
Muratet JP; Daver A; Minier JF; Larra F
J Nucl Med; 1998 Sep; 39(9):1546-50. PubMed ID: 9744340
[TBL] [Abstract][Full Text] [Related]
10. Randomised comparison of 1.1 GBq and 3.7 GBq radioiodine to ablate the thyroid in the treatment of low-risk thyroid cancer: a 13-year follow-up.
Ahtiainen V; Vaalavirta L; Tenhunen M; Joensuu H; Mäenpää H
Acta Oncol; 2020 Sep; 59(9):1064-1071. PubMed ID: 32603613
[No Abstract] [Full Text] [Related]
11. "High-dose" radioiodine therapy in advanced differentiated thyroid carcinoma.
Menzel C; Grünwald F; Schomburg A; Palmedo H; Bender H; Späth G; Biersack HJ
J Nucl Med; 1996 Sep; 37(9):1496-503. PubMed ID: 8790201
[TBL] [Abstract][Full Text] [Related]
12. Fractionated dosage of radioiodine for the ablation of low-risk differentiated thyroid cancer has no impact on survival.
Woliński K; Czepczyński R; Stangierski A; Trojanowski M; Rewaj-Łosyk M; Ziemnicka K; Bączyk M; Dyzmann-Sroka A; Ruchała M
Endokrynol Pol; 2018; 69(3):230-234. PubMed ID: 29504625
[TBL] [Abstract][Full Text] [Related]
13. One size does not fit all: the merit of absorbed doses to the blood in 131I therapy for differentiated thyroid carcinoma.
Fatholahi L; Tabeie F; Pashazadeh AM; Javadi H; Assadi M; Asli IN
Health Phys; 2015 Jan; 108(1):53-8. PubMed ID: 25437520
[TBL] [Abstract][Full Text] [Related]
14. Differentiated thyroid carcinoma in children and adolescents. Clinical characteristics, treatment and outcome of 15 patients.
Arici C; Erdogan O; Altunbas H; Boz A; Melikoglu M; Karayalcin B; Karpuzoglu T
Horm Res; 2002; 57(5-6):153-6. PubMed ID: 12053086
[TBL] [Abstract][Full Text] [Related]
15. Stunning with 131I diagnostic whole-body imaging of patients with thyroid cancer.
Gerard SK; Dam HQ
Radiology; 2005 Mar; 234(3):972-3; author reply 973-4. PubMed ID: 15734947
[No Abstract] [Full Text] [Related]
16. Testicular function after radioiodine therapy in patients with thyroid cancer.
Rosário PW; Barroso AL; Rezende LL; Padrão EL; Borges MA; Guimarães VC; Purisch S
Thyroid; 2006 Jul; 16(7):667-70. PubMed ID: 16889490
[TBL] [Abstract][Full Text] [Related]
17. Estimation of Second Primary Cancer Risk After Treatment with Radioactive Iodine for Differentiated Thyroid Carcinoma.
Corrêa NL; de Sá LV; de Mello RC
Thyroid; 2017 Feb; 27(2):261-270. PubMed ID: 27762670
[TBL] [Abstract][Full Text] [Related]
18. The role of radioactive iodine in the treatment of advanced differentiated thyroid carcinoma.
Pelikan DM; Lion HL; Hermans J; Goslings BM
Clin Endocrinol (Oxf); 1997 Dec; 47(6):713-20. PubMed ID: 9497879
[TBL] [Abstract][Full Text] [Related]
19. Lowest effective 131I activity for thyroid remnant ablation of differentiated thyroid cancer patients. Dosimetry-based model for estimation.
Jentzen W; Moldovan AS; Ruhlmann M; Görges R; Bockisch A; Rosenbaum-Krumme S
Nuklearmedizin; 2015; 54(3):137-43. PubMed ID: 25987357
[TBL] [Abstract][Full Text] [Related]
20. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
Jarzab B; Handkiewicz-Junak D; Wloch J
Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
